Relation between migraine pattern and white matter hyperintensities in brain magnetic resonance imaging

Mohamed Negm1*, Ahmed Mohamed Housseini2, Mohamed Abdelfatah1 and Alshimaa Asran3

Abstract

Background: Migraine is a common disorder in general population. Presence of white matter hyperintensities (WMHs) in brain MRI of migraine patients was not studied clearly. Detection of the prevalence of white matter hyperintensities in migraine patients determines its correlation with migraine severity, type and duration.

Methods: Cross sectional analytic study was conducted on migraine patients attending neurology clinic Suez Canal University Hospital. Sixty-five patients with migraine aged from 18 to 50 years were included. We excluded smokers and patients with hypertension, cardiac disease, diabetes mellitus, endocrine dysfunction, oncological and hematological diseases, infectious diseases, demyelinating disorders, and Alzheimer disease. Brain MRI and laboratory investigation was done for all patients.

Results: White matter hyperintensities were significant more frequent in migraine with aura than those without aura. According to MIGSEV scale, white matter hyperintensities were highly significantly more frequent in grade III severity than grades II and I. The number of white matter hyperintensities increases significantly with increase intensity of pain during attack. The number of white matter hyperintensities increases significantly with increase intensity of nausea, disability, tolerability during attack and age. Resistance to treatment also shows statistically significant difference in increase number of WMHs.

Conclusions: White matter hyperintensities are present in 43.1% of migraine patients. Age, presence of aura, nausea, disability during attack, resistance to treatment, and severity of headache and duration of migraine are considered a risk factor for development of white matter hyperintensities.

Keywords: Migraine, Aura, White matter hyperintensities (WMHs), MIGSEV scale

Background

Headache disorders are among the most common disorders of the nervous system (World Health Organization 2017). Migraine is the third most common disease globally affecting 14.7% general population worldwide (Steiner et al. 2013). In Egypt, migraine prevalence was 10.51% among different types of headache (Kandil et al. 2016). According to the Burden of Disease Study 2013, migraine was the sixth highest cause of disability worldwide, measured in years of life lost to disability (YLDs) (Global Burden of Disease Study 2013 Collaborators 2015).

After imaging era, migraine is not thought to be a benign disease as it was before. Kruit et al. (2004a) consider migraine to be an independent risk factor for structural brain changes in magnetic resonance imaging (MRI) like deep white matter hyperintensities, silent posterior circulation territory infarcts, and infratentorial hyperintense lesions.

White matter hyperintensities (WMH) are referred to lesions that appeared in MRI that has infarction features but did not cause any clinical symptoms or other stroke-related signs. These lesions have common distribution in subcortical and deep white matter. In migraine with aura patients, WMH were found in deep white matter in 47% and in the periventricular region in 19% in contrast to small vessel disease where WMH found...
mainly at periventricular region (Masuda et al. 2001). These lesions found to be clinically important as WMH found to be associated with increasing cognitive impairment and increasing the risk of dementia by twofolds, while increasing risk for stoke by threefolds (Debette and Markus 2010). Also, WMH increase the risk of late onset depression (Herrmann et al. 2007), physical disability (Sachdev et al. 2005), and Parkinson’s disease (Beyer et al. 2006).

The aim of this work was to identify the prevalence of white matter hyperintensities among migraine patients and to determine the correlation between white matter hyperintensities and migraine severity, type and duration.

Methods
The study was carried out as cross-sectional analytic study. We included 65 migraine patients aged from 18 to 50 years old attending the neurology clinic, Suez Canal University Hospital, and fulfilling the International Headache Society (IHS) criteria of migraine (Cephalalgia 2013). We excluded smokers and patients with hypertension, dyslipidemia, diabetes mellitus, hyperthyroidism, cardiac disease, history suggestive of any malignancy, and family history of Alzheimer disease. We excluded also patients with history suggestive of vascular, demyelinating, infection or other disorders with CNS pathology and patients with focal neurologic deficits and psychiatric illness.

Complete medical history done for all selected subjects. Assessment of migraine severity had done by using MIGSEV scale (El Hasnaoui et al. 2004) as follow:

A. Intensity of pain: (1) mild, (2) moderate, (3) intense, (4) very intense
B. Duration of attack, h: (1) < 4, (2) 4–12, (3) 12–24, (4) > 24
C. Nausea: (1) non, (2) mild, (3) intense, (4) vomiting
D. Disability: (1) no, (2) mild, (3) marked, (4) confined to bed
E. Tolerability: (1) tolerable, (2) barely tolerable, (3) intolerable
F. Resistance to treatment: (1) no, (2) yes
G. Frequency of attacks: (1) < 4/year, (2) 5–10/year, (3) 1–2/month, (4) 1/week, (5) > 1/week

Severity of migraine defined according to the main four component factors of the MIGSEV scale (Intensity of pain, Disability, Tolerability and Nausea) as: low (grade1) if at least 1 of the 4 items with a minimum score, and no item with a maximum score; high (grade 3) if at least 1 of the 4 items with a maximum score, and no item with a minimum score OR at least 2 items with a maximum score; and intermediate (grade 2) is all other cases.

Full clinical examination including neurological evaluation was done for detection of patients with focal neurological deficit. The following laboratory investigations were done for all the patients: lipid profile, fasting blood glucose, and thyroid-stimulating hormone levels.

Imaging protocol
Brain MRI was done for all patients. All MRI studies were carried out at Radiology Department, Suez Canal University Hospital, using 1.5 Tesla MR Imager (Achieva; Philips Medical Systems, Best, Netherlands). Circularly polarized clinical head coils were used in all patients. Sequences done are T1-weighted spin-echo sequence (Repetition Time “TR”/Echo Time “TE”: 450/15), T2-weighted turbo spin-echo sequence (TR/TE: 2455/110; echo train length “ETL”: eight), FLAIR (Fluid Attenuation Inversion Recovery) sequence (TR/TE: 6000/120; inversion time “TI”: 2000) and diffusion weighted (DW) images with the b value = 1000 s/mm². The matrix was 256 × 256, and the slice thickness was 5 mm, with a gap of 1 mm for all pulse sequences. For standard and accurate axial slice positioning, the anterior and posterior commissural line (AC-PC line) was used as a reference for T2-weighted and FLAIR images.

Image analysis
All original DICOM images were transferred to Philips workstation for image analysis by the same radiology consultant (AM Housseini, with 16 years of experience as a general radiologist) who was blinded to the clinical data of patients. White matter hyperintensities, either unilateral or bilateral, are detected as high-signal-intensity punctate foci on T2WI and FLAIR images most commonly in the white matter of the centrum semiovale, contrary to small high-signal-intensity lesions seen at deep white matter of ischemic brain changes. Patients were divided into two groups: those with white matter hyperintense punctate foci and those without any lesions. WMH were considered if visible as hyperintense on T2-weighted and FLAIR images, without hypointensity on T1-weighted scans, and were larger than 3 mm.

Statistical analysis
Data were fed to the computer and analyzed using IBM SPSS software package version 20.0 (Armonk, NY: IBM Corp) (Kirkpatrick and Feeney 2013). Qualitative data were described using number and percent. The Kolmogorov-Smirnov test was used to verify the normality of distribution. Quantitative data were described using range (minimum and maximum), mean, standard deviation, and median. p value is considered as significant when p < 0.05 and highly significant when p < 0.01.

The used tests were Mann Whitney test (for abnormally distributed quantitative variables, to compare
between two studied groups); Kruskal Wallis test (For abnormally distributed quantitative variables, to compare between more than two studied groups, and Post Hoc “Dunn’s multiple comparisons test” for pairwise comparisons); and Spearman coefficient (to correlate between two distributed abnormally quantitative variables).

**Ethical approval and consent to participation**
The study protocol was approved by the ethics committee of the Faculty of Medicine of Suez Canal University 20 July, 2016, registration number is 2877.

The purpose of the study was explained, and an informed written consent was taken before taking any data or doing any investigations. The participants were informed that their participation was voluntary and that they could withdraw from the study at any time without consequences. The participants were assured that all data will be considered confidential and will not be used outside this research. At the end of this study, records will be destroyed appropriately.

**Results**
This study included 65 patients with migraine. Their age ranged from 18 to 50 years with mean age 28.98 ± 10.16 years. Forty-eight patients (73.8%) were females, and 17 patients (26.2%) were males.

We found that 55 patients (84.6%) of the patients had migraine without aura and 10 patients (15.4%) had migraine with aura; 8 of them has visual aura and 2 has sensory aura. According to severity of migraine, 32 patients (49.2%) were grade I, 20 patients (30.8%) were grade II, and 13 patients (20.0%) were grade III. Thirty-three patients (50.8%) of the studied patients had migraine for less than 5 years, and 18 (27.7%) patients had migraine for 5–10 years, while 10 patients (15.4%) had migraine for 10–15 years, and 4 patients (6.2%) had migraine for more than 15 years.

According to MIGSEV scale: intensity of pain showed that 22 patients (33.8%) had mild pain, 27 patients (41.5%) had moderate pain, 6 patients (9.2%) had intense pain, and 10 patients (15.4%) had very intense pain. According to duration of headache attack, 17 patients (26.2%) had attacks less than 4 h, 27 patients (41.5%) had attacks last for 4–12 h, 11 patients (16.9%) had attacks last for 12–24 h, and 10 patients (15.4%) had attacks last for more than 24 h (Table 1).

According to nausea scale, 33 patients (50.8%) had no nausea, 21 patients (32.3%) had mild nausea, 7 patients (10.8%) had intense nausea, and 4 patients (6.2%) had vomiting. According to disability during attack, 31 patients (47.7%) had no disability, 22 patients (33.8%) had mild disability, 8 patients (12.3%) had marked disability, and 4 patients (6.2%) became confined to bed. According to tolerability of headache during attack, 44 patients (67.7%) had tolerable headache, 16 patients (24.6%) had barely tolerable headache, and 5 patients (7.7%) had intolerable headache. According to resistance to treatment, 54 patients (83.1%) did not have resistance, while 11 patients (16.9%) had resistance (Table 2).

According to number of white matter hyperintensities in MRI, 28 patients had white matter hyperintensities (43.1%), six of them had one lesion (9.2%) (Fig. 1), nine patients had 2 lesions (13.8%) (Fig. 2), and the rest 13

### Table 1 MIGSEV scale in studied cases (n = 65)

| Pain intensity during attack | No. | %  |
|-----------------------------|-----|----|
| Mild                        | 22  | 33.8|
| Moderate                    | 27  | 41.5|
| Intense                     | 6   | 9.2 |
| Very intense                | 10  | 15.4|

### Table 2 MIGSEV scale in studied cases (continued) (n = 65)

| Nausea | No. | %  |
|--------|-----|----|
| None   | 33  | 50.8|
| Mild   | 21  | 32.3|
| Intense| 7   | 10.8|
| Vomiting| 4  | 6.2 |

| Disability during attack | No. | %  |
|--------------------------|-----|----|
| No                       | 31  | 47.7|
| Mild                     | 22  | 33.8|
| Marked                   | 8   | 12.3|
| Confined to bed          | 4   | 6.2 |

| Tolerability during attack | No. | %  |
|----------------------------|-----|----|
| Tolerable                 | 44  | 67.7|
| Barely tolerable          | 16  | 24.6|
| Intolerable               | 5   | 7.7 |

| Resistance to treatment | No. | %  |
|-------------------------|-----|----|
| No                      | 54  | 83.1|
| Yes                     | 11  | 16.9|
patients had more than 2 lesions (20.0%) with the highest number is 9 lesions with mean 1.22 ± 1.83 lesions.

There was no statistical significant difference detected between white matter hyperintensities as regard to sex. White matter hyperintensities were statistically significant more frequent in migraine with aura with median (2.90 ± 2.60) with maximum number of hyperintensities 9 lesions, while in migraine without aura the median was (0.91 ± 1.49) with maximum number of 6 lesions. There was no statistical significant difference detected between type of aura and white matter hyperintensities. According to grade of migraine, white matter hyperintensities were highly statistically significant more frequent in grade III severity with median (2.62 ± 2.69) with maximum number of hyperintensities 9 lesions, while grade II severity has median (1.55 ± 1.73) and maximum number of hyperintensities 6 lesions, and finally grade I severity has median (0.44 ± 0.88) and maximum number of hyperintensities 3 lesions. There was no statistical significant difference detected between duration of migraine and white matter hyperintensities (Table 3).

The number of white matter hyperintensities found to increase significantly with increase intensity of pain during attack as mean number of hyperintensities in very intense pain (3.0 ± 2.91), intense pain (2.0 ± 1.26), moderate pain (0.93 ± 1.57), and mild pain (0.55 ± 0.96). While duration of attack and frequency of attacks show no statistical significant difference in number of white matter hyperintensities (Table 4).

The number of white matter hyperintensities was found to increase significantly with increase intensity of nausea during attack as mean number of hyperintensities in patients who had vomiting (2.75 ± 2.50), intense nausea (2.29 ± 1.89), mild nausea (1.38 ± 1.66), and those did not have nausea (0.70 ± 1.70). Also disability and tolerability during attack show statistically significant difference in increase number of white matter hyperintensities. Mean number of hyperintensities to those patients confined to bed (2.0 ± 2.83), marked disability (2.38 ± 1.77), mild disability (1.82 ± 2.28), and those had no disability was 0.39 ± 0.76. While mean number of hyperintensities who had intolerable headache was 3.0 ± 2.24, barely tolerable 2.25 ± 2.54, and those had tolerable headache 0.64 ± 1.08. At the last, resistance to treatment also shows statistically significant difference in increase number of white matter hyperintensities as mean number of hyperintensities in patients who had resistance to treatment was 2.27 ± 1.74 and those who did not have resistance to treatment was 1.0 ± 1.79 (Table 5).

According to multivariate analysis, neither gender nor duration of attack had statistically difference, but age, migraine severity grade, pain intensity during attack, nausea, disability, and tolerability had a highly statistically significant difference,
while migraine duration and resistance to treatment had a statistically significant difference (Table 6).

**Discussion**

In our study, we found that the prevalence of WMHs in migraine patients is 43.1% with different numbers of hyperintensities. This was consistent with Le Pira et al. 2013a who estimated the prevalence to be 43.2%. Similarly, Seneviratne et al. 2013a also estimated the prevalence to be 43%. A higher prevalence was reported by Rossato et al. 2010 who estimated it to be 56.4% among migraineurs with aura; their high frequency might be due to studying patients who had migraine with aura only. Whereas a lower prevalence was noted in other studies (Zeytin et al. 2014 (11.53%), Toghae et al. 2015 (32.2%), Zhang et al. 2016 (32%), and Trauninger et al. 2011 (31.18%)), the low incidence in these studies may be because of different methodology.

Our study showed that there is no statistical significance as regard to sex and the presence of WMHs. This finding was supported by other studies (Toghae et al. 2015; Zhang et al. 2016; Trauninger et al. 2011; Gomez-Beldarrain et al. 2016; Chong and Schwedt 2015; Hamedani et al. 2013; Kruit et al. 2004b).

In our study, presence of WMHs was higher in migraine with aura than migraine without aura. This comes
in accordance with Le Pira et al. 2013b, Bashir et al. 2013, and Kruit et al. 2010. This could be explained by fluctuations in cerebral blood flow associated with hypoperfusion or hypoperfusion which modulated by cortical spreading depression from recurrent aura attacks that affect micro-vascular hemodynamics leading to ischemic injury (Rothwell 2010). In the opposite side, Zhang et al. 2016 and Hamedani et al. 2013 showed that migraine without aura had more WMHs load than those with migraine with aura. While other studies (Toghae et al. 2015; Trauninger et al. 2011; Seneviratne et al. 2013b) show that there was no difference between migraine subtype and WMHs, which may be due to differences in patient selection and sample size.

In our study, the high grade of severity of migraine was associated with more WMHs load than those with migraine with aura. While other studies (Toghae et al. 2015; Trauninger et al. 2011; Seneviratne et al. 2013b) show that there was no difference between migraine subtype and WMHs, which may be due to differences in patient selection and sample size.

In our study, the high grade of severity of migraine was associated with more WMHs load than those with migraine with aura. While other studies (Toghae et al. 2015; Trauninger et al. 2011; Seneviratne et al. 2013b) show that there was no difference between migraine subtype and WMHs, which may be due to differences in patient selection and sample size.

Table 5 Number of WMH and MIGSEV parameters (continued)

| N  | Number of WMH in MRI | Test of sig. | p     |
|----|----------------------|--------------|-------|
|    | Min.-Max. | Mean ± SD | Median |
| Nausea |
| None | 23 | 0.0–9.0 | 0.70 ± 1.70 | 0.0 | H = 10.590* | 0.014* |
| Mild | 21 | 0.0–5.0 | 1.38 ± 1.66 | 1.0 |
| Intense | 7 | 0.0–5.0 | 2.29 ± 1.89 | 2.0 |
| Vomiting | 4 | 0.0–6.0 | 2.75 ± 2.50 | 2.50 |
| Disability during attack |
| No | 31 | 0.0–2.0 | 0.39 ± 0.76 | 0.0 | H = 14.054* | 0.003* |
| Mild | 22 | 0.0–9.0 | 1.82 ± 2.28 | 1.0 |
| Marked | 8 | 0.0–5.0 | 2.38 ± 1.77 | 2.50 |
| Confined to bed | 4 | 0.0–6.0 | 2.0 ± 2.83 | 1.0 |
| Tolerability during attack |
| Tolerable | 44 | 0.0–4.0 | 0.64 ± 1.08 | 0.0 | H = 11.860* | 0.003* |
| Barely tolerable | 16 | 0.0–9.0 | 2.25 ± 2.54 | 2.0 |
| Intolerable | 5 | 0.0–6.0 | 3.0 ± 2.24 | 3.0 |
| Resistance to treatment |
| No | 54 | 0.0–9.0 | 1.0 ± 1.79 | 0.0 | U = 151.5* | 0.005* |
| Yes | 11 | 0.0–5.0 | 2.27 ± 1.74 | 3.0 |

H, p—H and p values for Kruskal Wallis test. U, p—U and p values for Mann Whitney test. WMH white matter hyperintensities
*Statistically significant at p ≤ 0.05.

Table 6 Multivariate analysis of development of WMH among migraineurs

| Number of WMH in MRI | r_s | p     |
|----------------------|-----|-------|
| Age (years) | 0.419* | 0.001* |
| Males | −0.037 | 0.768 |
| Migraine severity grade | 0.462* | < 0.001* |
| Migraine duration | 0.276* | 0.026* |
| Attack duration | 0.211 | 0.092 |
| Pain intensity | 0.404* | 0.001* |
| Nausea | 0.402* | 0.001* |
| Disability | 0.444* | < 0.001* |
| Tolerability | 0.428* | < 0.001* |
| Resistance to treatment | 0.353* | 0.004* |

r_s Spearman coefficient. WMH white matter hyperintensities
*Statistically significant at p ≤ 0.05

There was no significant relation between the presence of WMHs and duration of migraine by years. This finding was supported by most of the other previous studies (Zhang et al. 2016; Le Pira et al. 2013b; Bashir et al. 2013; Seneviratne et al. 2013b; Szabó et al. 2012). On the other hand, Toghae et al. 2015 found a significant correlation between duration of migraine and WMHs. Also, Trauninger et al. 2011 concluded that patients with migraine disease more than 20 years had WMHs more frequent than patients with migraine disease less than 20 years. That contradiction might be because in our study most of migraineurs had migraine less than 10 years. Only 4 patients had migraine for more than 15 years.
In our study, increased intensity of pain of headache during attack had a significant relation to increased WMHs incidence. Toghae et al. 2015 did not find the same relation; use of different scales to assess the intensity of pain may be the explanation. On other hand, both attack duration and frequency did not have significant relation to develop WMHs in our study which might suggest that these changes are specific to migraine and not only to the chronic, repeated painful condition. These results were supported by other studies (Rossato et al. 2010; Toghae et al. 2015; Zhang et al. 2016; Szabó et al. 2012). On other hand, Seneviratne et al. 2013b and Trauninger et al. 2011 considered attack frequency is associated to WMHs, explained by tissue damage during attacks caused by local inflammatory responses and excessive neuronal activation during attacks. This contradiction in results may be due to differences in patient selection and sample size.

In our study, disability, tolerability during attacks of headache, and intensity of nausea were found to have high statistical significance in increasing number of WMHs. Also resistance to medical treatment as a sign of severity of migraine was strongly related to WMHs development. On other hand, Kruit et al. 2010 and Toghae et al. 2015 found no significant relation between the use of prophylactic drug use and WMHs.

Age was detected in our study to be a risk factor to develop WMHs in migraineurs. This might be because of increasing age means increase number of years lived with migraine which leads to more WMHs. Most of previous studies support our results (Rossato et al. 2010; Toghae et al. 2015; Zhang et al. 2016; Le Pira et al. 2013b; Seneviratne et al. 2013b). Meanwhile, Gomez-Beldarrain et al. 2016, Bashir et al. 2013, and Trauninger et al. 2011 show no relation between age and WMHs in migraineurs, which might be because of migraine itself decrease in frequency and severity with increasing age which means it remit with age.

Using Spearman’s correlation coefficient, we found that there is highly statistically positive correlation between WMHs and migraine severity grade according to MIGSEV scale, disability during attack and tolerability during attack making them the most important risk factors in developing WMHs that should to be controlled. While age, migraine duration, intensity of pain, nausea and resistance to treatment were found to be statistically correlated to WMHs, sex and attack duration were not statistically correlated.

The major strength points of our study is its clinical-based design, the standardized diagnosis of migraine according to International headache society criteria, and the sensitive MRI protocol that was read by an experienced neuroradiologist blinded to clinical data minimizing the possibility that lesions were misclassified. Limitations of the study included small sample size because of the strict selection criteria. Also the use of 3-T MRI could better visualize smaller lesions.

Conclusions
In conclusion, migraine is commonly associated with WMHs (43.1%). Age, presence of aura, nausea, and disability during attack, resistance to treatment, and severity of headache and duration of migraine are considered a risk factor for development of WMHs, although WMHs were detected more frequent in grade III severity of migraine that is considered an association.

Abbreviations
IH: International Headache Society; WMH: White matter hyperintensities

Availability of data and materials
The paper is a part of thesis conducted in the Faculty of Medicine, Suez Canal University, and approved by its ethical committee. The data can be publicly available at the Faculty of Medicine, Suez Canal University.

Authors’ contributions
MN was responsible for the design of the study and guidance, follows up the final revision, and prepared the paper’s final revision. AMH was responsible for the guidance and follows up the final revision. MA was responsible for the guidance and follows up the final revision. AA was responsible for the practical work, was involved in the design of the study, and performed the statistical analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study protocol was approved by the ethics committee of the faculty of Medicine of Suez Canal University, 20 July, 2016, registration number is 2877. The purpose of the study was explained, and an informed written consent was taken before taking any data or doing any investigations. The participants were informed that their participation was voluntary and that they could withdraw from the study at any time without consequences. The participants were assured that all data will be considered confidential and will not be used outside this research. At the end of this study, records will be destroyed appropriately.

Consent for publication
All participants had signed an informed consent to participate and for the data to be published.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Neurology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
2Diagnostic Radiology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
3Neuropsychiatry, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.

Received: 29 January 2018 Accepted: 26 August 2018
Published online: 10 September 2018

References
Bashir A, Lipton R, Ashina S, Ashina M. Migraine and structural changes in the brain: a systematic review and metaanalysis. Neurology. 2013;81(14):1260–8.
Beyer M, Aarsland D, Greve O, Larsen J. Visual rating of white matter hyperintensities in Parkinson’s disease. Mov Disord. 2006;21(2):223–9.
Rossato G, Adami A, Thijs V, Cerini R, Pozzi-Mucelli R, Mazzucco S, Anzola G, Sette Rothwell P. Limitations of the usual blood-pressure hypothesis and importance of Toghae M, Rahimian E, Abdollahi M, Shoar S, Naderan M. The prevalence of Seneviratne U, Chong W, Billimoria P. Brain white matter hyperintensities in Seneviratne U, Chong W, Billimoria P. Brain white matter hyperintensities are Steiner T, Stovner L, Birbeck G. Migraine: the seventh disabler. J Headache Pain. Masuda J, Nabika T, Notsu Y. Silent stroke: pathogenesis, genetic factors and Le Pira F, Reggio E, Quattrocchi G, Sanfilippo C, Maci T, Cavallaro T, Zappia M. Le Pira F, Reggio E, Quattrocchi G, Sanfilippo C, Maci T, Cavallaro T, Zappia M. Gomez-Beldarrain M, Oroz I, Zapirain B, Ruano B, Fernandez Y, Cabrera A, Anton-Ladislao A, Aguirre-Larraceoecha U, Garcia-Monco J. Right fronto-insular white matter tracts link cognitive reserve and pain in migraine patients. J Headache Pain. 2016;17(1). Hamedani A, Rose K, Peterlin B, Mosley T, Coker L, Jack C, Knopman D, Alonso A, Gottstein R. Migraine and white matter hyperintensities: the ARIC MRI study. Neurology. 2013;81(15):1308–13. Hermann L, Le Masurier M, Ebmeier K. White matter hyperintensities in late life depression: a systematic review. J Neurol Neurosurg Psychiatry. 2007;79(6): 619–24. Kandill M, Hamed S, Fadel K, Khalifa H, Ghanem M, Mohamed K. Migraine in Assiut Governorate, Egypt: epidemiology, risk factors, comorbid conditions and predictors of change from episodic to chronic migraine. Neurrol Res. 2016;38(3):232–41. Kirkpatrick L, Feeney B. In: Student, editor. A simple guide to IBM SPSS statistics for version 20.0. Belmont: Wadsworth, Cengage Learning; 2013. Krutt M, van Buchem M, Hofman P, Bakkers J, Terwindt G, Ferrari M, Launer L. Migraine as a risk factor for subclinical brain lesions. JAMA. 2004a;291(4):427–34. Krutt M, van Buchem M, Hofman P, Bakkers J, Terwindt G, Ferrari M, Launer L. Migraine as a risk factor for subclinical brain lesions. JAMA. 2004b;291(4):427–34. Krutt M, van Buchem M, Launer L, Terwindt G, Ferrari M. Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: the population-based MRI CAMERA study. Cephalalgia. 2010;30(2):129–36. Le Pira F, Reggio E, Quattrocchi G, Sanfilippo C, Maci T, Cavallaro T, Zappa M. Executive dysfunctions in migraine with and without aura: what is the role of white matter lesions? Headache. 2013a;54(1):125–30. Le Pira F, Reggio E, Quattrocchi G, Sanfilippo C, Maci T, Cavallaro T, Zappa M. Executive dysfunctions in migraine with and without aura: what is the role of white matter lesions? Headache. 2013b;54(1):125–30. Masuda J, Nabika T, Notou Y. Silent stroke: pathogenesis, genetic factors and clinical implications as a risk factor. Curr Opin Neurol. 2001;14(1):77–82. Rossato G, Adams A, Thijs V, Ceirini R, Pozzi-Mucelli R, Mazzucco S, Anzola G, Sette M, Dina L, Menghetti G, Zanferoni C. Cerebral distribution of white matter lesions in migraine with aura patients. Cephalalgia. 2010;30(7):855–9. Rothwell P. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010;375(9718):938–48. Sachdev P, Wen W, Christensen H, Jorm A. White matter hyperintensities are related to physical disability and poor motor function. J Neurol Neurosurg Psychiatry. 2005;76(3):362–7. Seneviratne U, Chong W, Billimoria P. Brain white matter hyperintensities in migraine: clinical and radiological correlates. Clin Neurol Neurosurg. 2013a; 115(7):1040–3. Seneviratne U, Chong W, Billimoria P. Brain white matter hyperintensities in migraine: clinical and radiological correlates. Clin Neurol Neurosurg. 2013b; 115(7):1040–3. Steiner T, Stovner L, Birbeck G. Migraine: the seventh disabler. J Headache Pain. 2013;14(1). Szabó N, Kincses Z, Párducz A, Tajti I, Szok D, Tuka B, Király A, Babos M, Vörös E, Bombosi G, Orfi Z, Feczko L. White matter microstructural alterations in migraine: a diffusion weighted MRI study. Pain. 2012;153(3):651–6. Toghae M, Rahimian E, Abdollahi M, Shoar S, Naderan M. The prevalence of magnetic resonance imaging Hyperintensity in migraine patients and its association with migraine headache characteristics and cardiovascular risk factors. Oman Med J. 2015;30(3):203–7. Trauninger A, Leel-Öszy E, Ramson D, Pótó L, Aradi M, Kóvér F, Imre M, Komáromy H, Erdélyi-Botor S, Patzkó A, Pfund Z. Risk factors of migraine-related brain white matter hyperintensities: an investigation of 186 patients. J Headache Pain. 2011;12(1):97–103. World Health Organization. (2017). Headache disorders. Available: http://www. who.int/mediacentre/factsheets/fs277/en/ [Accessed 14 Aug. 2017]. Zeytin A, Tok S, Dogan N. The frequency and localization of white matter lesions in migraine patients with or without aura in Anatolia, Turkey. Int J Acad Res. 2014(2):337–9. Zhang Q, Datta R, Detre J, Cucchiara B. White matter lesion burden in migraine with aura may be associated with reduced cerebral blood flow. Cephalalgia. 2016;37(6):517–24.